These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 9487539)

  • 1. Evaluation of the proposed FDA pilot dose-response methodology for topical corticosteroid bioequivalence testing.
    Singh GJ; Fleischer N; Lesko L; Williams R
    Pharm Res; 1998 Jan; 15(1):4-7. PubMed ID: 9487539
    [No Abstract]   [Full Text] [Related]  

  • 2. Revisiting FDA's 1995 Guidance on Bioequivalence Establishment of Topical Dermatologic Corticosteroids: New Research Based Recommendations.
    Ozdin D; Sharma N; Lujan-Zilbermann J; Colucci P; Kanfer I; Ducharme MP
    J Pharm Pharm Sci; 2018; 21(1):413-428. PubMed ID: 30407906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioequivalence Study Methods with Pharmacokinetic Endpoints for Topical Ophthalmic Corticosteroid Suspensions and Effects of Subject Demographics.
    Harigaya Y; Jiang X; Zhang H; Chandaroy P; Stier EM; Pan Y
    Pharm Res; 2018 Nov; 36(1):13. PubMed ID: 30443681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the proposed FDA pilot dose-response methodology for topical corticosteroid bioequivalence testing.
    Demana PH; Smith EW; Walker RB; Haigh JM; Kanfer I
    Pharm Res; 1997 Mar; 14(3):303-8. PubMed ID: 9098871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transfer of the experimental methodology described in the FDA guidance for corticosteroid bioequivalence testing to pharmacodynamic effects caused by nicotinates.
    Remane Y; Leopold CS
    J Cosmet Dermatol; 2006 Dec; 5(4):289-93. PubMed ID: 17716246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic analysis of the FDA guidance for industry--'Topical dermatologic corticosteroids: in vivo bioequivalence'.
    Leopold CS
    Eur J Pharm Biopharm; 2003 Jul; 56(1):53-8. PubMed ID: 12837481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application of the Food and Drug Administration (FDA) bioequivalent guidance of topical dermatological corticosteroid in yellow-skinned Japanese population: validation study using a chromameter.
    Keida T; Hayashi N; Kawashima M
    J Dermatol; 2006 Oct; 33(10):684-91. PubMed ID: 17040497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bioequivalence of topical dermatological dosage forms--methods of evaluation of bioequivalence. AAPS/FDA Workshop on 'Bioequivalence of Topical Dermatological Dosage Forms-- Methods of Evaluating Bioequivalence', September 4-6, 1996, Bethesda, Md.
    Shah VP; Flynn GL; Yacobi A; Maibach HI; Bon C; Fleischer NM; Franz TJ; Kaplan SA; Kawamoto J; Lesko LJ; Marty JP; Pershing LK; Schaefer H; Sequeira JA; Shrivastava SP; Wilkin J; Williams RL
    Skin Pharmacol Appl Skin Physiol; 1998; 11(2):117-24. PubMed ID: 9603663
    [No Abstract]   [Full Text] [Related]  

  • 9. Development of in vivo bioequivalence methodology for dermatologic corticosteroids based on pharmacodynamic modeling.
    Singh GJ; Adams WP; Lesko LJ; Shah VP; Molzon JA; Williams RL; Pershing LK
    Clin Pharmacol Ther; 1999 Oct; 66(4):346-57. PubMed ID: 10546918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioequivalence (bioavailability) of generic topical corticosteroids.
    Jackson DB; Thompson C; McCormack JR; Guin JD
    J Am Acad Dermatol; 1989 May; 20(5 Pt 1):791-6. PubMed ID: 2715430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The topical corticosteroid classification called into question: towards a new approach.
    Humbert P; Guichard A
    Exp Dermatol; 2015 May; 24(5):393-5. PubMed ID: 25707534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing individual bioequivalence using the structural equation model.
    Carrasco JL; Jover L
    Stat Med; 2003 Mar; 22(6):901-12. PubMed ID: 12627408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioequivalence Methodologies for Topical Drug Products: In Vitro and Ex Vivo Studies with a Corticosteroid and an Anti-Fungal Drug.
    Leal LB; Cordery SF; Delgado-Charro MB; Bunge AL; Guy RH
    Pharm Res; 2017 Apr; 34(4):730-737. PubMed ID: 28097506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. On sample sizes for bioequivalence studies with inhaled corticosteroids.
    Wijnand HP; de Vos D
    Eur J Clin Pharmacol; 1997; 52(4):325-7, 329-30. PubMed ID: 9248775
    [No Abstract]   [Full Text] [Related]  

  • 15. Broader picture surrounding new pediatric labeling for topical corticosteroid therapy.
    D'Alonzo GE
    J Am Osteopath Assoc; 1999 Jan; 99(1):15-6, 18. PubMed ID: 9972090
    [No Abstract]   [Full Text] [Related]  

  • 16. Factors impacting the combination of topical corticosteroid therapies for psoriasis: perspectives from the International Psoriasis Council.
    van de Kerkhof PC; Kragballe K; Segaert S; Lebwohl M;
    J Eur Acad Dermatol Venereol; 2011 Oct; 25(10):1130-9. PubMed ID: 21564329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bioequivalence of topical corticosteroids: a regulatory perspective.
    Williams RL
    Int J Dermatol; 1992 Oct; 31 Suppl 1():2-5. PubMed ID: 1428462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Practical aspects of topical corticosteroid selection.
    Kircik LH
    J Drugs Dermatol; 2012 Dec; 11(12):s3-4. PubMed ID: 23547331
    [No Abstract]   [Full Text] [Related]  

  • 19. A contract research organization's response to the new FDA guidances for bioequivalence/bioavailability studies for orally administered drug products.
    Kimanani E; Stypinski D; Curtis G; Stiles M; Heessels P; Logan S; Nelson K; St Germain E; Boswell G
    J Clin Pharmacol; 2000 Oct; 40(10):1102-8. PubMed ID: 11028249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kelsey's Commandos: FDA investigates the investigators.
    Small WE
    Am Pharm; 1979 Jun; 19(6):30-3. PubMed ID: 463736
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.